Testing the Effects of an Algorithm for Neuropathic Pain on Patient and System Outcomes - Full Text View

Sponsored by:	Dartmouth-Hitchcock Medical Center
Information provided by:	Dartmouth-Hitchcock Medical Center
ClinicalTrials.gov Identifier:	NCT00130130

Purpose

The overall purpose of this project is to improve nurse skills regarding neuropathic pain (NP) assessment, treatment and referral practices through implementation of an evidence-based algorithm and to improve selected patient outcomes as a result of algorithm use.

Condition	Phase
Pain	Phase I Phase II

U.S. FDA Resources

Study Type:	Observational
Study Design:	Case-Only, Prospective
Official Title:	Testing the Effects of an Algorithm for Neuropathic Pain on Patient and System Outcomes

Further study details as provided by Dartmouth-Hitchcock Medical Center:

Primary Outcome Measures:

To implement an evidence based screening, assessment, treatment, and referral guideline for hematology/oncology patients with NP receiving care [ Time Frame: outcome measures will consist of the NPVAS, and a PPCPS adapted rom the original project. Adequate satisfaction will be defined as 25% or mor of all patients reporting being very or completely satisfied as measured by PPCPS ]

Biospecimen Retention: None Retained

Biospecimen Description:

Estimated Enrollment:	50
Study Start Date:	August 2005
Estimated Study Completion Date:	August 2006

Detailed Description:

Neuropathic pain (NP) is defined as pain that arises from injury, disease or dysfunction of the central or peripheral nervous system. For the patient focused phase of the project NP treatment will be guided via the Peripheral Neuropathy Treatment Algorithm. Patients will receive algorithm-specific treatment for 12 weeks.

Eligibility

Ages Eligible for Study:	18 Years to 90 Years
Genders Eligible for Study:	Both
Accepts Healthy Volunteers:	No
Sampling Method:	Non-Probability Sample

Study Population

Cancer patients experiencing NP from a variety of causes

Criteria

Inclusion Criteria:

Cancer patients experiencing NP from a variety of causes
NP Visual Analogue Scale (VAS) score equal to or > 4 with 12 week estimated duration
Karnofsky Performance Status (KPS) 60% or greater
Age greater than 18

Exclusion Criteria:

Patients undergoing anticancer or invasive pain procedures specifically intended to palliate NP are ineligible

Contacts and Locations

Please refer to this study by its ClinicalTrials.gov identifier: NCT00130130

Locations

United States, New Hampshire
Dartmouth Hitchcock Medical Center
Lebanon, New Hampshire, United States, 03756

Sponsors and Collaborators

Dartmouth-Hitchcock Medical Center

Investigators

Principal Investigator:

Ellen Lavoie-Smith, ARNP

Dartmouth-Hitchcock Medical Center

More Information

Study ID Numbers:	D 0403, ONS
Study First Received:	August 12, 2005
Last Updated:	November 15, 2007
ClinicalTrials.gov Identifier:	NCT00130130
Health Authority:	United States: Institutional Review Board

Study placed in the following topic categories:

Pain

ClinicalTrials.gov processed this record on January 16, 2009